Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1087301

Bio-Naive Crohn's Disease Patients with Long- Standing Disease Benefit from Ustekinumab Treatment: Real World Experience


(Univerzitetni klinični center Ljubljana) Tomašić, Vedran; Drobne, David; Borzan, Vladimir; Bišćanin, Alen; Hanžel, Jurij; Oršić Frič, Vlasta; Ćaćić, Petra; Štabuc, Borut; Ogresta, Doris; Kralj, Dominik et al.
Bio-Naive Crohn's Disease Patients with Long- Standing Disease Benefit from Ustekinumab Treatment: Real World Experience // United European Gastroenterology Journal, 8 (2020), 8_suppl; 330-330 doi:10.1177/2050640620927345 (međunarodna recenzija, ostalo)


CROSBI ID: 1087301 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Bio-Naive Crohn's Disease Patients with Long- Standing Disease Benefit from Ustekinumab Treatment: Real World Experience
(UEG Week 2020 Poster Presentations)

Autori
Tomašić, Vedran ; Drobne, David ; Borzan, Vladimir ; Bišćanin, Alen ; Hanžel, Jurij ; Oršić Frič, Vlasta ; Ćaćić, Petra ; Štabuc, Borut ; Ogresta, Doris ; Kralj, Dominik ; Dorosulić, Zdravko ; Hrabar, Davor

Kolaboracija
Univerzitetni klinični center Ljubljana

Izvornik
United European Gastroenterology Journal (2050-6406) 8 (2020), 8_suppl; 330-330

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, ostalo, ostalo

Ključne riječi
ustekinumab, Crohn disease

Sažetak
Introduction: Ustekinumab (UST) is a human anti- IL12/23 p40 monoclonal antibody, approved for treatment of Crohn’s Disease (CD). This multicenter, non-interventional, retrospective chart review explored robust real-life data in patients receiving UST to access long-term efficacy and treatment persistence of UST treatment in the bio- naive CD population with long-standing disease. Aims & Methods: Clinical data, such as maintenance of clinical response using Harvey-Bradshaw index, combined steroid-free and biochemical clinical remission, endoscopic response/healing via the simple endoscopic score for Crohn’s disease (SES-CD), dose escalation and treatment persistence were assessed in 42 adult patients (55% female ; mean age 46 ± 15.1 years ; mean BMI 25.28 ± 4.5 kg/m2 ) with long-standing (mean duration of 10, 5 years) biologic-naive CD from 3 tertiary centers (one Slovenian and two Croatian) between January 2018 and April 2020. Data were collected before first infusion, at week (W)24, W52, as well as last follow-up. Results: At W24 84% (35/42) of CD patients had achieved clinical response and 38.1% (16/42) were in combined steroid-free and biochemical clinical remission. After an average of 16 months of treatment duration, 88.1% (37/42) of CD patients were still on UST treatment, 71.4% (30/42) had maintained clinical response and 35.7% (15/42) were in sustained steroidfree clinical remission. The number of patients requiring steroid treatment was reduced by 87%. Mean HBI decreased from 8 to 3 and SES-CD from 6 to 2. The majority [59.53%] of patients started ustekinumab as monotherapy, i.e. without concomitant immunomodulator medication. 31% of patients experienced UST dose escalation. Conclusion: UST offers an effective and persistent steroid sparing treatment option in this real-life multicenter study of bio-naive CD patients with long-standing disease

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti



POVEZANOST RADA


Ustanove:
Medicinski fakultet, Zagreb,
KBC "Sestre Milosrdnice"

Profili:

Avatar Url Davor Hrabar (autor)

Avatar Url Petra Ćaćić (autor)

Avatar Url Vedran Tomašić (autor)

Avatar Url Alen Bišćanin (autor)

Citiraj ovu publikaciju

(Univerzitetni klinični center Ljubljana) Tomašić, Vedran; Drobne, David; Borzan, Vladimir; Bišćanin, Alen; Hanžel, Jurij; Oršić Frič, Vlasta; Ćaćić, Petra; Štabuc, Borut; Ogresta, Doris; Kralj, Dominik et al.
Bio-Naive Crohn's Disease Patients with Long- Standing Disease Benefit from Ustekinumab Treatment: Real World Experience // United European Gastroenterology Journal, 8 (2020), 8_suppl; 330-330 doi:10.1177/2050640620927345 (međunarodna recenzija, ostalo)
(Univerzitetni klinični center Ljubljana) (Univerzitetni klinični center Ljubljana) Tomašić, V., Drobne, D., Borzan, V., Bišćanin, A., Hanžel, J., Oršić Frič, V., Ćaćić, P., Štabuc, B., Ogresta, D. & Kralj, D. (2020) Bio-Naive Crohn's Disease Patients with Long- Standing Disease Benefit from Ustekinumab Treatment: Real World Experience. United European Gastroenterology Journal, 8 (8_suppl), 330-330 doi:10.1177/2050640620927345.
@article{article, year = {2020}, pages = {330-330}, DOI = {10.1177/2050640620927345}, keywords = {ustekinumab, Crohn disease}, journal = {United European Gastroenterology Journal}, doi = {10.1177/2050640620927345}, volume = {8}, number = {8\_suppl}, issn = {2050-6406}, title = {UEG Week 2020 Poster Presentations}, keyword = {ustekinumab, Crohn disease} }

Časopis indeksira:


  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus


Citati





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font